These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, Piccirillo N, Chiusolo P, Sorà F, Innocenti I, Sica S, Leone G. Ann Hematol; 2008 Nov 10; 87(11):891-8. PubMed ID: 18587576 [Abstract] [Full Text] [Related]
12. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide]. Nikitin EA, Stadnik EA, Lorie IuIu, Biderman BV, Tsyba NN, Salogub GN, Kolosheĭnova TI, Kolosova LIu, Risinskaia NA, Zaritskiĭ IuA, Kovaleva LG, Sudarikov AB. Ter Arkh; 2007 Jan 01; 79(7):66-70. PubMed ID: 17802794 [Abstract] [Full Text] [Related]
13. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L. Eur J Haematol; 2011 Nov 01; 87(5):426-33. PubMed ID: 21749447 [Abstract] [Full Text] [Related]
15. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. J Clin Oncol; 2009 Sep 20; 27(27):4578-84. PubMed ID: 19704063 [Abstract] [Full Text] [Related]
16. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianní L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S. Cancer; 2005 Dec 15; 104(12):2743-52. PubMed ID: 16284990 [Abstract] [Full Text] [Related]
17. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM. J Clin Oncol; 2011 Sep 10; 29(26):3559-66. PubMed ID: 21844497 [Abstract] [Full Text] [Related]
18. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. Athanasiadou A, Stamatopoulos K, Tsompanakou A, Gaitatzi M, Kalogiannidis P, Anagnostopoulos A, Fassas A, Tsezou A. Cancer Genet Cytogenet; 2006 Jul 15; 168(2):109-19. PubMed ID: 16843100 [Abstract] [Full Text] [Related]